Aclaris Therapeutics, Inc. (ACRS) is a biopharmaceutical company that is committed to the discovery, development, and commercialization of therapeutics to address significant needs in dermatology, immunology, and oncology. Based in Wayne, Pennsylvania, the company began operations in 2012 and, over time, has built a reputation in the research and treatment of skin ailments, including common warts and seborrheic dermatitis.
Aclaris is best known for developing ESKATA (Hydrogen Peroxide) Topical Solution, the first-ever FDA-approved, non-invasive treatment for raised seborrheic keratosis, a common non-cancerous skin condition. Aclaris sold the worldwide rights to ESKATA in 2019 to focus on new drug development in the immunology and oncology fields.
In its quest for innovative treatments, Aclaris has focused on kinase inhibition, which blocks certain proteins that contribute to the overactive immune response in various diseases. One of its key kinase inhibitors, ATI-450, is currently in the development phase and results from clinical trials have shown promise in the treatment of rheumatoid arthritis and other immune disorders.
The company is also committed to targeted oncology and is developing a series of drugs to treat various types of cancer. Aclaris's ATP-competitive and immunokinase-focused strategy aims to combat the complexities of cancer-causing agents at a cellular level.
In the financial markets, Aclaris Therapeutics trades under the symbol "ACRS" on the NASDAQ. The company has seen a steady growth and is appreciated by investors for its robust research and development pipeline, strategic focus, and commitment to addressing unmet needs in dermatology, immunology, and oncology.
Aclaris maintains a progressive corporate culture built on ethics, collaboration, and scientific excellence. The company's mission is to translate the best science into important new treatments and bring transformational therapies to people who need them.
Over the years, Aclaris Therapeutics Inc. has proven its dedication to being a leader in the medical industry. With an unwavering commitment to innovation, the company offers new hope for patients facing some of the most challenging diseases. As it continues to grow and push boundaries, Aclaris upholds its vision to be a leading biopharmaceutical company innovating to improve lives.
In essence, Aclaris Therapeutics, Inc. stands at the forefront of medical innovation with a relentless commitment to clinical excellence, research, and patient care. With a strong focus on dermatology, immunology, and oncology, the company continues to make significant strides in bringing groundbreaking treatments to market, thereby improving the quality of life for many patients.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) priced a $50.0 million public offering on October 27, 2026, following positive Phase Ib results for its anti-TSLP/IL-4Rα bispecific antibody, ATI-052, in atopic dermatitis and asthma. The company plans to prioritize Phase IIb development of ATI-052 in eosinophilic esophagitis (EoE), with a trial expected in early 2027. The offering covers 14,285,714 shares and pre-funded warrants, with notable investors participating.
Aclaris Therapeutics Inc. (NASDAQ: ACRS) reported positive Phase 1b clinical trial results for its bispecific antibody ATI-052, demonstrating efficacy and a favorable safety profile in patients with atopic dermatitis and asthma. The studies validated ATI-052's dual-target approach for TSLP, IL-4, and IL-13, showing rapid therapeutic responses. Aclaris plans to prioritize Phase 2b development for ATI-052 in eosinophilic esophagitis and has raised $50 million through a stock and warrant sale to strengthen its balance sheet.
Aclaris Therapeutics (NASDAQ:ACRS) announced positive Phase 1b results for ATI-052 in both atopic dermatitis and asthma, with both trials meeting their primary safety objectives. The atopic dermatitis trial showed a 45% placebo-adjusted improvement in eczema severity, while the asthma trial recorded a 59% reduction in an airway inflammation marker. Aclaris plans to prioritize a Phase 2b trial of ATI-052 for eosinophilic esophagitis next year and will provide updates on additional indications.
Aclaris Therapeutics, Inc. announced positive primary analysis results from its Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma, demonstrating rapid and broad responses, validating the additive/synergistic potential of targeting TSLP, IL-4, and IL-13. ATI-052 showed a favorable safety profile with no conjunctivitis. The company plans to prioritize Phase 2b development of ATI-052 in Eosinophilic Esophagitis (EoE) and will provide updates on potential additional indications.
Aclaris Therapeutics, Inc. has priced an underwritten public offering to raise approximately $50 million. The offering includes 7,785,714 shares of common stock at $3.50 per share and pre-funded warrants for 6,500,000 shares for certain investors. The proceeds will support the development of product candidates for immuno-inflammatory diseases, with the offering expected to close on October 28, 2026.